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Tissue inhibitor of metalloproteinase (TIMP) was purified and molecularly cloned on the basis of its erythroid.potentiating ctivity (EPA). 
TIMP/EPA appears to be a bifunctional molecule with both growth factor and anti-enzymatic ctivity. Recently, a ~g~ond TINlP-relatcd molecule 
was identified and we have investigated its possible rythroid-lmtentiating ctivity. Native, purified human TIMP-2 was assayed for erythroid. 
potentiating activity using an in vitro erythroid burst formation assay and was compared with that of previoasly characterized r combinant 
EPA/TIMP-I. The results demonstrate that both members ofthe tissue inhibitor of metalloproteinase f mily, TIMP-i and TIMP-2, pos~cs~d 
erythroid potentiating activity which was inhibited by antibodies developed toneutralize EPA. These restdt~ suggest that TIMP-2 shares a common 
structural domain with EPA/TIMP-I that is r¢sponsibl¢ for the erythroid-potentiating ctivity ofthe~ inhibitors. Therefore, TIMP-I and TIMP-2, 
with both anti-proteaae activity and growth factor activity, join a family of bifunctional molecules such as libroblast growth factor and thrombin 
which have both enzymatic and growth factor activity. 
Metalloproteinase inhibitor; Collagenase inhibitor; Erythropoiesis; CFU.E; BFU-E 
1. INTRODUCTION 
Although erythropoietin is the primary regulator of 
erythropoiesis, several other proteins have been 
identified which are capable of erythropoiesis in vitro. 
The stimulating effects of these non-erythropoietin mo- 
lecules were identified by in vitro erythroid colony as- 
says to detect either burst-promoting activity (BPA) or 
enhancement of colony formation by more mature 
erythroid precttrsors (CFU-E) [1-5]. While early studies 
were conducted with unpurified preparations, several of 
the cloned myeloid colony-stimulating factors (CSFs) 
have been shown to enhance rythropoiesis in vitro, and 
in some cases in vivo. These CSFs include interleukin-3 
(IL-3), granulocyte-macrophage CSF (GM-CSF) and 
granulocyte CSF (G-CSF) [6-8]. Also, platelet-derived 
growth factor (PDGF), activin, fibroblast growth factor 
(FGF) growth hormone, insulin and insulin-like growth 
factor- 1 (IGF- 1) augment erythropoiesis in vitro [9-15]. 
We identified an erythroid-potentiating activity (EPA) 
in the supernatant of the HTLV-II-transformed human 
T-lymphblast cell line (Me), and purified the 28 000 Da 
glycoprotein molecule to homogeneity [5,16]. Subse- 
quent eDNA cloning demonstrated that EPA was 
identical to tissue inhibitor of metalloproteinases 
(TIMP, TIMP-1) [17,18], which can be isolated from a 
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variety of human tissues and body fluids and which has 
been shown to inhibit the eollagenase family of enzymes 
[19-21]. The purified natural EPA and, subsequently, 
the recombinant EPA were shown to augment colony 
formation by human CFU-E, BFU-E and K-562 cells 
[16,17,22,23]. We were also able to demonstrate specific 
binding of radioiodinated recombinant EPA to the K- 
562 erythroleukemia cells [23]. 
Recently, we have isolated and characterized a novel 
protease inhibitor which upon direct amino acid se- 
quencing appears closely related to EPA/TIMP-I 
[24,25]. This inhibitor, which we refer to as TIMP-2, 
was initially isolated as a complex with the 72 000 Da 
type IV collagenase/gelatinase pro nzyme from the con- 
ditioned media of haman melanoma cells [17]. This 
complex has also been isolated from endothelial cells 
[26]. Dissociation of this complex and subsequent pu- 
rification demonstrated that TIMP-2 is a 21 000 Da 
non-glycosylated protein that is dependent on internal 
disulfide bridges to maintain its inhibitory effect on 
collagenolytic activity. Subsequent eDNA cloning of 
TIMP-2 revealed that direct amino acid sequencing was 
correct in 95% of the residue assignments [25]. Compa- 
rison of the deduced amino acid sequence of TIMP-2 
with that of EPA/TIMP-I revealed 37% identity and 
67% overall similarity. The positions of all 12 cysteine 
residues were conserved, as were 3 out of 4 tryptophan 
residues. Also there were regions of the primary struc- 
ture of these proteins where the homology exceeded the 
average value of 67%, while there were other regions 
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where the homology between these proteins was re- 
duced. Thus it was postulated that specific domains 
within the structure of the TIMP could account for the 
common properties of these proteins, namely inhibition 
of collagenolytic activity, as well as domains unique to 
each protein that could account for unique properties 
such as the ability to bind to the latent forms of specific 
members of  the collagenase gene family [25]. In the 
present study we compare directly the erythroid-poten- 
tiating activity of recombinant EPA/T1MP- 1 and native 
TIMP-2. The results demonstrate hat like EPA/TIMP- 
1, TIMP-2 possesses erythroid-potentiating activity. 
Furthermore, this activity resides in a portion of the 
molecule that shares a common epitope with EPA and 
can be blocked by anti-EPA/TIMP-1 antibodies. 
2. MATERIALS AND METHODS 
2.1. Preparatiolt of TIMP.2 
Native human TIMP-2 was purified from the culture medium of 
human A2058 melanoma ceils [24] a~ previously described. Briefly, the 
latent 72 kDa, type IV eollagenase/gelatinase-TlMP-2 complex was 
isolated by gelatin affinity chromatography of the concentrated me- 
lanoma cell conditioned media. The purified complex was then dis- 
sociated and its components p~rified using reverse phase HPLC over 
a RP-300 column (Pierce Chemical Co,), The TIMP-2 containln8 peak 
was recovered, lyophilized, resuspended in distilled water and re- 
lyophilized to remove residual trifluoroacetie acid and/or acetonitrile, 
Material from this second freeze-dryin8 step was then resuspended in 
20 mM Tris-HCl, pH 7,5. and stored frozen at -80°C, The concentra- 
tion of purified TIMP-2 protein solutions were initially determined 
usin8 amino acid analysis and subsequently b the Bio-Rad method, 
2,2, Preparatfon of recombinant EPA 
Recombinant EPA was prepared as previously described [17] from 
medium conditioned by stably tranffected Chinese hamster ovary 
cells, which constitutively exprc~ high levels of EPA from integrated 
copies of the p91023 (B) vector containing the haman EPA eDNA 
clone, Briefly, serum-free medium was collected and the proteins con- 
centrated and fmctlonated by ~el filtration and reverse phase liquid 
chromatography using a Vydac (Western Analytical, Los Angeles) C-4 
column, The concentration of purified protein was determined by 
amino acid composition analysis and subsequently using the Bio-Rad 
method. 
2,3, Bioasaay for EPA 
Human peripheral blood BFU-E was assayed as described [14,16] 
by plating 3 x 10 ~ cells/ml peripheral blood nucleated cells in 
methyleellulose in 0,1 ml/microtiter well, Erythroid bursts containing 
a minimum of 50 hemoglobinized cells were scored at 7-14 days with 
an inverted microscope, Control wells typically contained 40--45 
bursts, Purified recombinant EPA or native TIMP-2 were diluted 
prior to assaying for EPA activity in 0.02% bovine serum albumin to 
give final concentrations between 0,02-1,8 nM, Diluent alone was 
added to control wells, 
2.4, Preparation of EPA-neutrali:Olg antibodies 
Antibodies to recombinant EPA were raised in rabbits and screened 
for their ability to neutralize EPA activity in vitro [22], Two polyclonal 
antibody preparations, Ab.A and Ab.B, which recognize EP.aJT. IMP- 
1 on Western blotting and which neutralize the in vitro stimulation of 
erythroid colony formation, were utilized in these experiments (~i£ts 
of Dr, Judith Gasson). 1 #1 aliquots of these antibodies were added 
to wells containing either £PA/TIMP-I or TIMP-2, The amount of 
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Fia. 1, Con~ntration dependence oferythroid-potentiating aetivil 
recombinant EPA/TIMP-I (0) and native, purified TIMP-2 (m,), 
peak of TIMP-2 activity occurs at 50 pM compared with the 
activity of recombinant EPA/TIMP-I which occurs at 80 pM 
antibody remained constant despite varying concentrations of ei 
EPA/rlMP.I or TIMP-2 (see Table 1). 
3. RESULTS 
3.1. EtTthroid-potentiating activity of TIMP-2 
The erythroid-potentiating activity of TIMP-2 , 
compared with that of recombinant EPA/TIMP-1 
experiments conducted in parallel. The results of  tl: 
assays were normalized against he diluent control ;
were expressed as a percent of control value. The res 
shown in Fig. 1 demonstrate hat TIMP-2 stimula 
the growth of erythroid burst-forming units (BFU 
over a concentration range that is similar to thai 
recombinant EPA/TIMP-1. The activity of TIMP-; 
these assays peaks at a concentration of 50 pM ct 
pared with the maximum for EPA/TIMP-I which 
curred at 80 pM. In these assays the number of eolo~ 
peaked at 202% of controls for EPA/TIMP-I and 2C 
of  controls for TIMP-2. The biological activity of 
tire, purified EPA/TIMP-1 has previously I: 
reported to be in the pM range [19,23]. The simila 
in the primary sequences, dilution profiles and pete 
of these preparations suggests that EPA/TIMP-I 
TIMP-2 stimulate rythroid colony formation thro 
a similar mechanism. 
3.2. Inhibition of TIMP-2 erythroid-potentiating actt
by EPA/T[MP-I neutralizing antibodies 
To test if the erythroid-potentiating " ":":" ' ,,c,,,,,y of tl 
TIMP species was due to related epitopes we util: 
EPA neutralizing antibody preparations, Ab-A and 
B. Optimized concentrations of EPA/TIMP-1 
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Table 1 
Concentra.  Control  • NRS + Ab-A  + Ab-B 
tion (pro) 
EPA/TIMP-1 
0 100 __. 2 100 _ 1 99 +, 1 100 __. 1 
20 141 _ 18 113 __. 1 85 +, 1 - 
50 162 + 33 121 _+ 1 84 +, 1 - 
70 180 ± 15 128 + 1 89 __. 2 145 + 1 
80 202 __. 14 159 ___ 6 92 +- 5 126 _+ 2 
90 163 ± 2 135 +_ 6 87 +, 4 105 _ 3 
T IMP.2 
0 100± 1 100~ I 100+ I ]00~ l 
20 184 + 19 140 ___ 14 87 + 3 146 
50 204± 15 157___ I1 96+4 113+_ 1 
70 159 + 16 138 +_ ? 87 + 3 112 + 1 
80 137 _+ 3 114 +_. 1 91 ± 5 - 
90 129 + 5 109_+ 1 98-+ 1 - 
NRS, normal  rabbit serum. 
TIMP-2 were tested in the presence of 1 btl of these 
antibody preparations. These EPA/TIMP concentra- 
tions ranged from 20-90 pM, as determined in the ex- 
periments shown in Fig. 1. Control experiments utiliz- 
ing normal rabbit serum were also conducted. The 
results of these studies are shown in Table 1. In the 
control experiments addition of normal rabbit serum 
resulted in a slight reduction of erythroid-potentiating 
activity when compared to experiments in which only 
TIMP-2 or EPA/TIMP-I was added. However, the 
addition of the antibody Ab-A resulted in inhibition of 
erythroid colony growth such that the values in these 
assays were always below that of the unstimulated con- 
trol. This was evident in experiments in which both 
EPA/TIMP-I and TIMP-2 were used to stimulate 
colony growth. Antibody Ab-B also inhibited the action 
of these agents but to a lesser degree. The ability of 
antibodies, developed to recognize and neutralize EPA/ 
T1MP-1, to also neutralize TIMP-2 activity in these 
assays uggests that the erythroid-potentiating activity 
of these species is contained within a common domain 
shared by EPA/TIMP-I and TIMP-2. 
4. DISCUSSION 
Our findings indicate that, like EPA/TIMP-I, TIMP- 
2 can stimulate the growth oferythroid precursors. The 
maximal effect for both TIMP-2 and EPA/TIMP-I was 
204 and 202%, respectively. This is consistent with 
previous reports in which the addition of recombinant 
human EPA/TIMP-I to cultures containing mono- 
nuclear human peripheral blood resulted in a near dou- 
bling of the number of BFU-E c,,,,,n,,.s^~ :° rlt,.,,.v'l ~'n In the 
present study TIMP-2 appears to be as effective, with 
the maximal effect occurring at a slightly lower con- 
centration of 50 pM compared with EPA/TIMP-1 
which had a maximal effect at 80 pM. Furthermore, 
based on the homology between these 2 proteins at the 
amino acid level, the similarity in their dilution profiles 
for erythroid-potentiating activity, and the similarity in 
the dose for maximum effect in these assays, we propose 
that TIMP-2 functions in a manner very similar to EPA/ 
TIMP-1 in stimulating erythroid colony growth. This is 
supported by experiments in which antibodies which 
neutralized the stimulatory effects of EPA/TIMP-I on 
erythroid colony growth also eliminated the effects of 
TIMP-2 on colony growth. 
The relationship between the mitogenic activity and 
the protease inhibitory properties of EPA/TIMP-I and 
TIMP-2 is presently unknown. The growth stimulation 
by these proteins is thought o be a direct cellular effect 
mediated by a cell surface receptor [23], and not through 
inhibition of metalloprotease activity, although the 
precise mechanism of the growth stimulation by EPA/ 
TIMP-I and TIMP-2 is yet to be defined. In other 
bifunctional molecules, uch as basic fibroblast growth 
factor and thrombin, the domains responsible for 
growth factor activity are physically distinct from either 
the enzyme-inducing or the esterolytically active se- 
quences 128,29]. By analogy, in the case of TIMP-1 and 
TIMP-2, we would expect he domains responsible for 
the growth factor activity to be distinct from the se- 
quences responsible for their metalloproteinase inhib- 
itory activity. Others have postulated that EPA may 
mediate its effect on erythropoiesis by modulating ery- 
thropoietin receptors [30]. Recent studies have demon- 
strated that EPA/TIMP-1 is effective when administ- 
ered in vivo at stimulating erythropoiesis in anemic mice 
or mice treated with crythropoietin [31,32]. This 
suggests that despite the disparity between the in vitro 
estimates of maximally effective doses (50-80 pM) for 
stimulating erythroid colony growth and the measure- 
ment of human serum levels of EPA/TIMP-I (5-20 nM) 
[33], the administration of exogenous recombinant 
EPA/TIMP-I may act synergistically in the stimulation 
of erythropoietin-driven erythopoiesis. 
In vivo administration of recombinant EPA/TIMP-I 
has also been shown to reduce lung colonization by 
highly invasive ras-transformed rat embryo fibroblasts 
[34]; however, it is felt that this effect is directly related 
to the protease inhibitory activity of the EPA/TIMP-I 
molecule as demonstrated in in vitro invasion assays 
[35]. TIMP-2 has also been shown to be effective in 
blocking tumor cell invasion in these assays [36,37]. 
Also, both EPA/TIMP-1 and TIMP-2 [38], as well as 
TIMP-related cartilage-derived inhibitors [39,40] have 
been shown to inhibit angiogenesis in rive. Although 
the exact mechanism of this inhibition has not been 
shown, the TIMP-related inhibitors have been shown to 
inhibit both endothelial v!! growth and endothelial cell 
migration in vitro [40]. These cartilage-derived inhi- 
biters show striking similarity to both EPA/TIMP-I 
[40] and TIMP-2 [39]. Whether these ffects on endothe- 
233 
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linl cells are mediated by direct binding to a cell-specific 
receptor or are the result of protease inhibition is not 
known. The diversity of these proposed roles for EPA/ 
TIMP-1 and TIMP-2 indicates that evolutionary con- 
servation has allowed a single molecule to subserve 
more than one physiologic activity, 
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